Science • Medicine

BioNTech records first successes in the development of a vaccine against multiple sclerosis

Mainz-based BioNTech is working on an mRNA-based vaccine against multiple sclerosis. The first preclinical studies are promising; the vaccine approach was able to prevent MS disease in mice, and in mice that were already mildly ill, it was able to prevent the disease from progressing and motor functions could even be restored. The study on the mice is so promising that the start of clinical trials on humans is now the next goal, although these cannot begin for at least two years, as the approach must first be tested on human cells in the laboratory.

feminist theologian and independent artist living in Berlin
Card reviewed by: @christoph